Carfilzomib shows therapeutic potential for reduction of liver fibrosis by targeting hepatic stellate cell activation

Abstract Because hepatic stellate cells (HSCs) play a major role in fibrosis, we focused on HSCs as a potential target for the treatment of liver fibrosis. In this study, we attempted to identify drug candidates to inactivate HSCs and found that several proteasome inhibitors (PIs) reduced HSC viabil...

Full description

Bibliographic Details

Published in:	Scientific Reports
Main Authors:	Ayana Fujiwara, Keisuke Takemura, Anna Tanaka, Misaki Matsumoto, Masato Katsuyama, Takeshi Okanoue, Kanji Yamaguchi, Yoshito Itoh, Kazumi Iwata, Kikuko Amagase, Atsushi Umemura
Format:	Article
Language:	English
Published:	Nature Portfolio 2024-08-01
Subjects:	Proteasome inhibitor Carfilzomib Hepatic stellate cell Liver fibrosis
Online Access:	https://doi.org/10.1038/s41598-024-70296-8